Statistics of Astrocytoma

Executive Summary

Astrocytoma has affected approximately 830 children and teenagers belonging to the age group below 19 years of age in the US region. Around 15% of Pilocytic astrocytoma has affected all brain and other CNS cancers of this age group. The 5-year survival rate of Astrocytoma represents 97% of the 5-year survival rate among children after diagnosis of the tumor in the case of pilocytic Astrocytoma, while the 5-year survival rate for diffuse astrocytoma patients is around 84%. Anaplastic Astrocytoma has a survival probability of slightly more than 27%. Children with non-infiltrating Astrocytoma represented a better 5-year survival rate.

Statistics of Astrocytoma

Based on the Statistics of Astrocytoma in the United States, an estimated 830 children and teenagers under 19 will be diagnosed with astrocytoma this year, while, Pilocytic astrocytoma account for around 15% of all brain and other CNS cancers in this age group ^​1​.

The 5-year survival rate of Astrocytoma indicates how many children survive for at least five years after a tumor is discovered. The percentage refers to how many out of 100 something is. Children and teenagers up to 19 who have pilocytic astrocytoma have a 97% 5-year survival rate. The 5-year survival rate for diffuse astrocytoma patients is around 84%. Anaplastic astrocytoma has a survival probability of slightly more than 27%.

On the other hand, the grade of astrocytoma has an impact on survival rates Astrocytoma. Other factors, such as how much of the tumor can be removed after surgery, impact survival rates. Children with non-infiltrating astrocytoma, a kind of astrocytoma that is unlikely to spread, had a better 5-year survival rate ^​2​.

It’s vital to keep in mind that statistics on astrocytoma survival rates for children are estimates. The figure is based on annual data on the number of children in the United States who have this malignancy. Experts also assess survival data every five years. As a result, the estimate may not reflect the outcomes of improved diagnosis or therapy that has been available for less than five years.

References